Clinical Trials List
Protocol Number202409007MIPE
Active
2024-10-01 - 2030-12-31
Phase II
Recruiting1
ICD-10C15.3
Malignant neoplasm of upper third of esophagus
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9150.0
Malignant neoplasm of cervical esophagus
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Single Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 江韻 Division of Hematology & Oncology
- JHE-CYUAN GUO Division of Hematology & Oncology
- JEI-YIE HUANG Division of Nuclear Medicine
- Chia-Hsien Chen Division of Hematology & Oncology
- 呂紹綸 Division of Hematology & Oncology
- FENG-MING HSU Division of Hematology & Oncology
- TA-CHEN HUANG Division of Hematology & Oncology
- 江旴恆 Division of General Surgery
- JANG-MING LEE Division of General Surgery
- 郭弘揚 Division of Hematology & Oncology
- 黃培銘 Division of General Surgery
- 吳宗哲 Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
- 陳克誠 Division of General Surgery
- MEI-FANG CHENG Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
50 participants
